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2e objective of this research was to develop a robust gene expression-based prognostic signature and scoring system for
predicting overall survival (OS) of patients with high-grade serous ovarian cancer (HGSOC). Transcriptomic data of HGSOC
patients were obtained from six independent studies in the NCBI GEO database. Genes signiﬁcantly deregulated and as-
sociated with OS in HGSOCs were selected using GEO2R and Kaplan–Meier analysis with log-rank testing, respectively.
Enrichment analysis for biological processes and pathways was performed using Gene Ontology analysis. A resampling/cross-
validation method with Cox regression analysis was used to identify a novel gene expression-based signature associated with
OS, and a prognostic scoring system was developed and further validated in nine independent HGSOC datasets. We ﬁrst
identiﬁed 488 signiﬁcantly deregulated genes in HGSOC patients, of which 232 were found to be signiﬁcantly associated with
their OS. 2ese genes were signiﬁcantly enriched for cell cycle division, epithelial cell diﬀerentiation, p53 signaling pathway,
vasculature development, and other processes. A novel 11-gene prognostic signature was identiﬁed and a prognostic scoring
system was developed, which robustly predicted OS in HGSOC patients in 100 sampling test sets. 2e scoring system was
further validated successfully in nine additional HGSOC public datasets. In conclusion, our integrative bioinformatics study
combining transcriptomic and clinical data established an 11-gene prognostic signature for robust and reproducible pre-
diction of OS in HGSOC patients. 2is signature could be of clinical value for guiding therapeutic selection and
individualized treatment.
1. Introduction
Ovarian cancer (OC) represents the most lethal gynaeco-
logical malignancy and the ﬁfth leading cause of death in
women, with a 5-year survival rate around 10% [1]. Due to
lack of early screening and diagnostic measures, most
patients are diagnosed with OC at an advanced stage.
Globally, more than 239,000 women are diagnosed with OC
and 152,000 succumb to this disease each year [2].
OC has been shown to have considerable complexity and
heterogeneity in biology, drug response, and survival time
[3], representing a major obstacle for its precision medicine
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practice. OCs of epithelial origin constitute approximately
90% of all the cases, whereas ovarian sex cord stromal tumor,
ovarian germ cell tumor, and secondary tumor of ovarian
metastasis (e.g., Krukenberg tumor) are less frequent [4].
High-grade serous ovarian carcinoma (HGSOC) is the most
predominant in epithelial OCs, accounting for 70–80% of
OC deaths [5].2emajority of HGSOCs can be grouped into
four subtypes based on gene overexpression levels speciﬁc
for each subtype: mesenchymal, immunoreactive, diﬀeren-
tiated, and proliferative [6].
HGSOC has been characterized by both genetic alter-
ations, including inherited BRCA gene mutations, TP53
mutations, DNA damage, chromosomal instability [6, 7],
and changes in RNA and miRNA expression and methyl-
ation status [8]. Microarray and next-generation sequencing
technologies have become vital tools for identifying these
changes genomewide, providing novel opportunities for the
identiﬁcation of biomarkers for diagnosis, prognosis, ther-
apeutic targets, and treatment response. For instance, many
multigene biomarkers based on transcription patterns have
been associated with prognosis across tumor types [9–14]. A
number of groups have sought to use genomewide gene
expression data to identify multigene signatures aimed at
predicting clinical outcomes, therapy responses, and sub-
types in OC [13–18]. Many existing signatures were gen-
erated using partial genome annotations, limited number of
patients, or used targeted gene selecting. 2us, it is very
much warranted to identify and develop clinically valuable
gene signatures for OC prognosis, especially when based on
comprehensive and unbiased whole-genome data.
In this study, we employed a multistep bioinformatic
strategy that uses omics information and clinical data to
build a gene expression prognostic scoring system in
HGSOC. We previously developed this approach to identify
and successfully validate a 53-gene signature associated with
OS of gastric cancer [11] and a 27-gene signature for lung
adenocarcinoma [12]. Here, we used ﬁfteen publicly avail-
able datasets of HGSOCs; six were used to identify an 11-
gene signature associated with patient prognosis using Cox
regression analysis and cross-validation. We then used nine
independent HGSOC datasets to validate the prognostic
scoring system and signature’s performance. Moreover, in
comparison with an existing 5-gene expression signature for
ovarian serous cystadenocarcinoma (CAC) [15], we showed
that our signature was superior in determining overall
survival for this type of epithelial ovarian carcinoma.
2. Materials and Methods
2.1. Patient Datasets. To broadly mine all the available in-
formation on HGSOCs, we have screened and used 15 in-
dependent datasets in the current study. Six public datasets
from the NCBI Gene Expression Omnibus (GSE18520,
GSE26712, GSE40595, GSE38666, GSE27651, and GSE2328)
provided the HGSOC gene transcript data to identify genes
diﬀerentially expressed between tumor and normal ovarian
tissues. TCGA HGSOC data were used to identify the gene
signature and develop the prognostic scoring system for
predicting OS of patients. Nine additional datasets
(GSE32063, GSE19829 GPL570, GSE30161, GSE3149, OV-
AU-ICGC, GSE14764, GSE9891, GSE 17260, and
GSE32062) were used for independent validation of the gene
signature and prognostic scoring system.
2.2. Statistical Analysis. By employing a 1.5-fold change
cutoﬀ and adjusted p-value <0.05, the diﬀerentially expressed
genes between normal versus HGSOC tissues were identiﬁed
with GEO2R. Diﬀerentially expressed genes associated with
OS in patients with HGSOC were selected using KM survival
analysis (Kaplan–Meier plotter (http://kmplot.com)) with a
hazard ratio (HR) with 95% conﬁdence intervals and log-rank
p value cutoﬀ for each gene at 0.05 [19].
2.3. Gene Ontology Pathway Analysis and Network
Construction. Metascape (http://www.metascape.org) was
used to assess overrepresentation of Gene Ontology cate-
gories in biological networks [20]. Cytoscape 3.4.0 (http://
www.cytoscape.org) was applied to generate and visualize
the gene coexpression networks, to better understand the
biological processes enriched, as well as their relationships in
the form of a network instead of the tabular text format
[21, 22]. Note that KEGG pathway (http://www.genome.jp/
kegg), GO Biological Processes (http://geneontology.org),
Reactome Gene Sets (http://www.reactome.org), and
CORUM (http://mips.helmholtz-muenchen.de/corum) were
ontology sources of gene network, pathway, and process
enrichment analysis.
2.4. Gene Expression Signature-Based Prognostic Risk Score.
Clinical data of HGSOC patients were obtained from the
TCGA dataset (http://cancergenome.nih.gov), with which
a biomarker panel associated with OS was reachable. 100
random selections of 307 patients from TCGA were
conducted and used as training sets. 2e remaining pa-
tients for each selection were used as test sets to validate
the reliability of the identiﬁed biomarker panel for
prognosis.
Forward conditional Cox regressions using SPSS were
carried out on each of the 100 training sets in order to isolate
the biomarker panel. Selected genes were recorded and those
that appeared in at least 20% of 100 training sets were in-
cluded in our biomarker panel. Subsequently, Cox re-
gression was repeated on all 100 training sets using our 11-
gene signature as covariates and using the forced entry
(enter) method to obtain the coeﬃcient values for each
biomarker. 100 coeﬃcients for every gene in the biomarker
panel were then obtained, and the average of them was used
to estimate the true coeﬃcient of each gene. A formula was
created to act as the prognostic scoring system, and all the
patients can get their scores accordingly:
∑
11
i�1
(gene i coefficient)∗ (gene i expression level). (1)
2e patients in the training sets were ranked by their
prognostic scores and divided into three equal-sized cohorts.
2e corresponding prognostic scores at cut points were
2 Journal of Oncology
recorded and averaged as the true cut point scores, with
which the patients in the test sets were also split into three
groups: “good”, “intermediate”, and “poor” groups. Dif-
ferences in OS among the three groups in all the test sets
were determined by constructing Kaplan–Meier plots and
performing log-rank tests.
2.5. Validation in IndependentDatasets andComparisonwith
an Existing Signature. 2e 11-gene biomarker panel was
further validated in nine independent datasets (Table S1).
New coeﬃcients for the 11 genes were obtained from Cox
regression. Prognostic scores for all patients were calculated,
and patients were ranked based on their scores and divided
into three equal-sized cohorts. Kaplan–Meier analysis and a
log-rank test were conducted to determine diﬀerences in
survival, as previously described [11, 12].
We compared the performance of our 11-gene signature
with a recently published 5-gene signature for prognosis of
ovarian serous CAC [15]. A multivariate Cox regression
analysis was conducted with the 5 genes on the same 100
training sets as described above for our inner validation.
Coeﬃcients for each of the 5 genes used in [15] and scores of
all 307 patients were calculated as above. 2en patients were
divided into tertiles (good, intermediate, and poor) based on
their prognostic scores, and the cut point scores were
recorded and averaged. Kaplan–Meier analysis was per-
formed, and a log-rank test was used to demonstrate dif-
ferences in OS among diﬀerent groups for all test sets.
3. Results
3.1. Identiﬁcation of Deregulated Genes in HGSOCs. To
identify genes that are consistently deregulated in HGSOC,
we performed a meta-analysis and compared gene transcript
levels in six publically available datasets containing tran-
scriptomic data for both HGSOC and normal ovarian tissues
(n� 397 from GSE18520, GSE26712, GSE40595, GSE38666,
GSE27651, and GSE2328) using GEO2R. For each dataset,
we compared HGSOC gene expression to gene expression in
normal ovarian tissues (Figure 1).
2e criteria for signiﬁcant diﬀerential expression for
each gene were set to a 1.5-fold change and adjusted p-value<0.05. A total of 562 probe IDs (260 downregulated and 302
upregulated) were consistently up- or downregulated across
all six datasets, representing 488 unique genes (222 down-
regulated and 266 upregulated) (Figure 1 and Table S2).
3.2. Analysis of Deregulated Genes and Overall Survival of
HGSOCs. 2e prognostic value for each of the 488
deregulated genes individually in HGSOC patients was
evaluated in a large public clinical database which integrates
gene expression and patient survival using Kaplan–Meier
survival analysis (Figure 2(a)). 2e eﬀects of high or low
expression levels of these genes on OS were assessed using
Kaplan–Meier survival analysis and compared statistically
using the log-rank test, with representative genes shown in
Figure 2(b). 2e results showed that 232 out of the 488 genes
were signiﬁcantly associated with OS (adjusted p-value
<0.05; Figure 2(b) and Table S3). 2e hazard ratio (HR) for
82 genes was <1 (higher gene expression associated with
good prognosis), which are referred as protective genes,
whereas 150 genes had a HR >1 (higher gene expression
associated with poor prognosis), which are considered risk
genes.
3.3. Gene Ontology (GO) Analysis of Prognostic Genes in
HGSOC. To understand the potential biological functions of
the 232 genes signiﬁcantly associated with OS in HGSOC
patients, we conducted Gene Ontology (GO) analysis using
Metascape and found signiﬁcant enrichment of many cel-
lular process and pathway-related genes associated with
cancer development including cell division, epithelial cell
diﬀerentiation, p53 signaling pathway, and vasculature de-
velopment (Figure 3(a) and Table S4). 2e interconnectivity
of related GO terms was visualized using Cytoscape where
individual GO terms are displayed as nodes connected based
on similarity (Figure 3(b)).
3.4. Establishment of an 11-Gene Prognostic Scoring System in
HGSOCs. Figure 4(a) shows the strategy we employed to
isolate a prognostic biomarker signature and to develop a
scoring system based on the 232 genes that were found to be
signiﬁcantly associated with OS in HGSOC patients. We ﬁrst
used a random resampling method to split 307 patients from
the TCGA dataset into 100 training (200 patients) and 100
testing (107 patients) sets.2e training sets were then used to
isolate a prognostic signature, and the testing sets were used
for validation. First, we performed a multivariate Cox re-
gression analysis in all 100 training sets to identify statis-
tically signiﬁcant independent genes within the 232 genes for
predicting OS. Genes that recurred in at least 20% of 100
training were assembled into an 11-gene signature:
RAD51AP1, CADPS2, DSE, ITGB8, PDE10A, GALNT10,
SNX1,MTHFD2, C9orf16, PYCR1, and ARL4 (Table S5). For
each of the 11 genes in the signature, gene function and
known roles in ovarian and other cancers are summarized in
Table S6.
A prognostic score for each cancer patient was used to
assess each patient’s risk of death and was deﬁned as the
linear combination of logarithmically transformed gene
expression levels weighted by average Cox regression co-
eﬃcients (Table S7) obtained from 100 training datasets
[11, 12]. 2e prognostic scores were assigned for all patients
in both training and test sets. In each training set, the pa-
tients were divided into tertiles based on their prognostic
score. 2e cutpoint scores were recorded and averaged for
each of 100 training sets. Based on the average scores, each
test set was split into three groups, i.e., good, intermediate,
and poor. We then performed Kaplan–Meier and log-rank
test analysis to determine signiﬁcant diﬀerences in OS
among diﬀerent groups for all test sets (Figure 4(b)). 2e
hazard ratios (HR) for the “intermediate” and “poor” groups
in comparison with the “good” groups were calculated for
each test set. In 99% of the test sets, patients in the “poor”
groups had a signiﬁcantly shorter OS than those in the
“good” groups (HR conﬁdence interval above “1”)
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(Figure 4(c), top panel), while in more than 60% of the test
sets, patients in the “intermediate” groups showed a sig-
niﬁcantly shorter OS than those in the “good” groups
(Figure 4(c), bottom panel). 2ese results validated the
discriminative ability of this 11-gene signature and prog-
nostic scoring system to stratify patients with good or worse
prognosis.
3.5. Independent Validation of the 11-Gene Scoring System.
To further validate our 11-gene signature, we tested it in nine
independent OC datasets (Table S1). Prognostic scores for all
patients were calculated and patients were ranked based on
their score. Signiﬁcant diﬀerences were identiﬁed using
Kaplan–Meier analysis across all nine datasets between
patient cohorts of “good” and “poor” prognosis. Patients
with a high prognostic score had a signiﬁcantly shorter OS
than those patients who scored low (p< 0.05) (Figure 5).2e
HR values range from 1.94 to 9.76 (Table S1) We conclude
that the 11-gene prognostic scoring system reproducibly
predicts overall survival of HGSOC patients.
3.6. Comparison with an Existing Prognostic Signature.
We compared the performance of our 11-gene signature
with a recently published 5-gene expression signature pre-
dicting clinical outcome of ovarian serous CAC [15] by
performing a multivariate Cox regression analysis using the
same strategy described in Figure 4 where for 100 training
sets, coeﬃcients for each of the 5 genes and scores of all the
307 patients were calculated.
Figure 6 shows the HR and 95% conﬁdence interval for
the “intermediate” and “poor” groups in comparison with
the “good” groups in the 100 test sets. For the 5-gene panel,
in 90% of the testing sets, patients in the “poor” groups had a
signiﬁcantly shorter OS than those in the “good” groups. For
the “intermediate” groups vs. “good” groups, only in 12% of
the testing sets, patients showed a signiﬁcantly shorter OS. In
comparison, for our 11-gene signature, these two numbers
are 99% and 61%, respectively. In addition, the median HR
of the 11-gene signature was on average 1.46-fold higher in
the “intermediate” vs. “good” groups and 1.73-fold higher in
the “poor” vs. “good” groups compared to the 5-gene sig-
nature (Figure 6). 2ese results indicate that the 11-gene
signature has discriminative ability for determining OS in
ovarian CAC patients, which is also signiﬁcantly superior to
the 5-gene panel.
4. Discussion
Identiﬁcation and development of reliable predictive bio-
markers and new therapeutic targets are critical for sig-
niﬁcantly improving cancer patient outcomes. 2e
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Figure 1: Human datasets of ovarian cancer and normal sample tissues. Samples were obtained from six independent gene transcript
datasets containing HGSOC and normal ovarian cases. To identify genes (common probe IDs) consistently deregulated in HGSOC, a fold-
change cutoﬀ of 1.5 and adjusted p-value <0.05 were used for each dataset.
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objective of this work was to use a multistep bioinformatics
analytic strategy we developed previously [11, 12] to an-
alyze six publicly available omics and clinical datasets to
generate a robust prognostic signature for patients with
HGSOC. We ﬁrst identiﬁed 232 genes associated with OS
that served as candidate markers to provide a prediction of
the prognosis of HGSOC patients. Eventually, we selected
an 11-gene prognostic signature and scoring system
showing strong discriminative power to separate patients
with good or poor survival. Moreover, the results were
independently validated in each of the nine independent
HGSOC datasets. We also demonstrated that our 11-gene
signature has higher predictive power compared to an
existing prognostic panel developed for ovarian serous
CAC. Taken together, the 11-gene signature could be of
translational value for clinical use. We are currently
working on the development of a multiplex high-
throughput assay to facilitate the clinical use of the sig-
nature. To date, there are still no clinically useful prognostic
biomarkers/scores in OC. However, two multigene ex-
pression-based scores, the Oncotype DX 21-gene breast
cancer assay developed by Genomic Health [9, 23] and the
MammaPrint 70-gene breast cancer recurrence assay by
Agendia [24], have been utilized to guide treatment de-
cisions, such as for adjuvant chemotherapy in breast cancer
[23]. 2ese two tests represent the ﬁrst prognostic gene
expression assays that have successfully passed multiple
independent clinical trials.
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Figure 2: Identiﬁcation of genes associated with prognostic function in HGSOC. (a) 2e 562 consistently deregulated probe IDs identiﬁed
represent 488 genes in the cancer patients.2rough Kaplan–Meier survival analysis, 232 genes were found to be signiﬁcantly associated with
overall survival of HGSOC patients. Functional annotation was carried out for the 232 genes. (b) Examples of Kaplan–Meier survival curves
for four individual genes signiﬁcantly associated with overall survival in HGSOC patients, which was divided into two groups to maximize
the diﬀerence in survival using log-rank testing between groups. We used HR and log-rank p-value for the curve comparison between the
groups.
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Microarray and next-generation sequencing technolo-
gies broadened the accessibility of large cancer genomewide
expression proﬁles. Taking advantage of these unbiased
genomewide approaches, we established multigene signa-
tures for predictive and prognostic purposes, including the
11-gene signature described in this study. To discover a
novel panel of prognostic biomarkers is the ﬁrst step in
developing a practically valuable assay/score in a clinical
setting. 2e next steps include multicenter clinical trials and
prospective trials that allow further validation of the eﬃcacy
and accuracy of the signature, in order to make a successful
clinical translation. It should be mentioned that microarray
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Figure 3: Gene Ontology analysis of 232 genes associated with OS. (a) Network layout of the clusters generated with the complete list of the
232 OS-associated genes in HGSOC. Each node represents one enriched term, where its size is proportional to the number of genes
associated with each term, and its color representing its cluster identity (i.e., nodes of the same color belong to the same cluster). All similar
terms with a kappa similarity score >0.3 are connected by edges (the thicker the edge, the higher the similarity). One term from each cluster
was selected to describe the general function of each cluster. Created by Metascape (http://metascape.org). (b) Top 20 most signiﬁcant GO
categories associated with the 232 genes.
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Figure 4: Continued.
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data-based analyses have generated many single and mul-
tiple gene biomarkers/signatures associated with prognosis
of speciﬁc types of cancers including OC. For OC, several
prognostic signatures have been developed based on dif-
ferent platforms, as described before. While these signatures
can predict OC survival, some of them were developed based
on limited patient numbers or conducted within a single
medical center. In addition, signatures developed in earlier
years were either based on incomplete genome annotations
or based solely on existing knowledge. Nevertheless, we
expect that with ongoing and future prospective studies,
some of these preclinical biomarker signatures, including the
11-gene signature described here, will be fully evaluated for
their value in the clinical settings.
Ovarian cancer, like many other cancers, occurs through
the accumulation of genetic alterations, which can result in
deregulation of gene expression. So far, there is still limited
information on the genes that are associated with prognosis
of OC. Table S6 summarizes the known functions for each
gene in the 11-gene panel in tumor development and
prognostic relevance. Of them, six have already been im-
plicated in the development and progression of HGSOCs in
previously published studies [25–31]. Six genes (RAD51AP1,
DSE, ITGB8, GALNT10, SNX1, and MTHFD2) were re-
ported to provide useful prognostic information about the
survival in various types of cancer [25, 27, 28, 32–36], in-
cluding three genes (RAD51AP1, ITGB8, and GALNT10)
which were reported to be prognostic for OC [25, 28, 32].
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Figure 4: Strategy to generate an 11-gene prognostic signature and its performance evaluation. (a) We employed multivariate Cox re-
gression analysis on 100 training sets through random sampling for the 232 genes and identiﬁed 11 genes selected into our Cox regression
model. Such a signature was used to generate a prognostic scoring system, which was further validated using 100 randomly assembled test
sets. (b) Representative Kaplan–Meier overall survival curves in two test sets. 2ese curves were separated into tertiles according to the
prognostic score calculated using the 11-gene signature. (c) HR values and their 95% conﬁdence interval across the 100 test sets, calculated
using a Cox model based on the prognostic score comparing poor vs. good (top) and intermediate vs. good (bottom).
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RAD51AP1, which encodes an RAD51 accessory protein,
participates in the homologous recombination DNA damage
response pathway. 2e ﬁnding in this study is in agreement
with DNA repair defects in HGSOCs. Upregulation of
RAD51AP1 predicted poorer OS in patients with ovarian
cancer [25]. DSE (SART2) gene has been shown to be fre-
quently upregulated in human brain tumors and other types
of cancer [37]. Moreover, elevated DSE expression in glioma
is associated with a worse tumor grade and poor OS [37].
Elevated levels were also detected in cervical, ovarian, and
endometrial cancers [34]. ITGB8 encodes a β-subunit of
integrin, and integrins play a regulatory role on cancer cells
through survival- and metastasis-related signaling pathways
[34]. Upregulation of ITGB8 has been shown in several types
of cancers, including HGSOCs. In addition, it was found that
its expression is an independent biomarker for predicting
unfavorable survival of patients with HGSOCs [27]. In-
tegrative network analysis of TCGA data has shown that
GALNT10 was highly predictive for the OS of ovarian cancer
patients [28]. 2ere is evidence that SNX1 may play a role in
tumorigenesis and its downregulation is signiﬁcantly corre-
lated with poor OS of colon cancer patients [29].MTHFD2 is
a gene associated with cancer development, and its high
expression is associated with poor prognosis of many types of
cancer, for example [36–38]. Five of these genes, CADPS2,
MTHFD2, PDE10A, PYCR1, and ARL4, have never been
reported to have a role in OC (Table S6). Interestingly, the
genes in the multigene panels reported in the literature, in-
cluding our 11-gene signature, are rarely overlapping, which
may reﬂect the disparity in tumor samples, microarray
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Figure 5: Validation of the 11-gene signature using four independent ovarian cancer cohorts. We analyzed the Kaplan–Meier plots
generated for the four cohorts used by applying the 11-gene signature. 2e patient cohort was split by the median based on the prognostic
index, and the log-rank p-values of the curve comparison between the risk groups and HR are shown. 2e HR values and 95% conﬁdence
intervals were calculated using Cox survival analysis.
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designs, database selection, and analytical approaches. 2e
genes in this signature may be novel potential therapeutic
targets for HGSOCs.
2e genes included in our signature might also be po-
tential biomarkers or targets for the treatment of OC.
Personalized treatment is often highlighted in today’s
clinical practice, where the molecular features such as ge-
netic background of an individual patient’s tumor determine
the prime treatment modalities. For example, Prexasertib
(LY2606368), a cell cycle checkpoint kinase 1 and 2 in-
hibitor, showed clinical activity and was tolerable in HGSOC
patients with BRCA wild-type disease [39].
In conclusion, as the most lethal gynaecological malig-
nancy, OC is undoubtedly a challenge for patients, medical
practitioners, and researchers. In this study, with an unbiased
multistep bioinformatics analytic strategy, we identiﬁed an
11-gene prognostic biomarker panel which robustly and
accurately predicts overall survival in patients with HGSOCs.
Gene Ontology analysis revealed several important enriched
cellular processes and pathways in HGSOCs. Together, our
results pave the way for developing a clinical assay for guiding
therapeutic selection and individualized treatment.
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signiﬁcantly associated with OS are highlighted in yellow.
Table S4: top 20 altered gene clusters identiﬁed in the 232
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